EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders

Michiel Beyens iD, Alessandro Toscano, Didier Ebo, Theo Gülen iD, Vito Sabato

Diagnostics · 14.12.2023 · 13 (24) · 3662

DOI: 10.3390/diagnostics13243662 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 14.12.2023. Verfasst von Michiel Beyens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, Department of Immunology, Allergology and Rheumatology, Infla-Med Centre of Excellence, University of Antwer…. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWO, Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Konsul T.H.C. Bergh Foundation, Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2). The upper limit of normal determined by the manufacturer is 11.4 ng/mL; however, this boundary has been the subject of debate. According to ECNM and AIM experts, the normal range of baseline tryptase should be 1 to 15 ng/mL. A genetic trait, hereditary alpha tryptasemia, characterized by an increased alpha coding TPSAB1 copy number is associated with a baseline value above 8 ng/mL. Elevated tryptase can also be found in chronic kidney disease, obesity, and hematological neoplasms. A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome. The goal of this review is to demonstrate the (in)significance of tryptase using some clinical vignettes and to provide a practical guide on how to manage and interpret an elevated tryptase level.

Schlagwörter

Stichwörter der Autor:innen

HaTMCASmastocytosistryptase

Autor:innen und Institutionen

  • Faculty of Medicine and Health Sciences, Department of Immunology, Allergology and Rheumatology, Infla-Med Centre of Excellence, University of Antwerp, 2610 Antwerp, Belgium.
  • Department of Immunology, Allergology and Rheumatology, University Hospital Antwerp, 2610 Antwerp, Belgium.
  • Department of Immunology and Allergology, AZ Jan Palfijn Gent, 9000 Ghent, Belgium.
  • Department of Respiratory Medicine and Allergy, K85, Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden.
  • Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, SE-17177 Stockholm, Sweden.

ORCID-Profile: Michiel Beyens, Theo Gülen

Förderung

  • FWO
  • Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek
  • Konsul T.H.C. Bergh Foundation, Sweden
  • Swedish Society of Medicine, Sweden

Zitieren

APA

Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V. (2023). Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. Diagnostics, 13(24), 3662. https://doi.org/10.3390/diagnostics13243662

Vancouver

Beyens M, Toscano A, Ebo D, Gülen T, Sabato V. Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. Diagnostics. 2023;13(24):3662. doi:10.3390/diagnostics13243662

BibTeX
@article{Beyens2023,
  author = {Beyens, Michiel and Toscano, Alessandro and Ebo, Didier and Gülen, Theo and Sabato, Vito},
  title = {Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {24},
  pages = {3662},
  doi = {10.3390/diagnostics13243662}
}
Kostenlos starten →